Press coverage about Phibro Animal Health (NASDAQ:PAHC) has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Phibro Animal Health earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.8796042736357 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Daniel M. Bendheim Sells 13,162 Shares of Phibro Animal Health Corp (PAHC) Stock (americanbankingnews.com)
- Daniel M. Bendheim Sells 6,576 Shares of Phibro Animal Health Corp (PAHC) Stock (americanbankingnews.com)
- Insider Selling: Phibro Animal Health Corp (PAHC) VP Sells 3,960 Shares of Stock (americanbankingnews.com)
- Phibro Animal Health Corp (PAHC) Major Shareholder Bfi Co., Llc Sells 12,000 Shares (americanbankingnews.com)
- Jack Bendheim Sells 36,000 Shares of Phibro Animal Health Corp (PAHC) Stock (americanbankingnews.com)
A number of brokerages recently issued reports on PAHC. ValuEngine upgraded Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th. BidaskClub upgraded Phibro Animal Health from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 6th. Morgan Stanley boosted their price objective on Phibro Animal Health from $30.00 to $36.00 and gave the company an “underweight” rating in a research note on Wednesday, February 7th. Credit Suisse Group boosted their price objective on Phibro Animal Health from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Tuesday, February 6th. Finally, Zacks Investment Research upgraded Phibro Animal Health from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research note on Thursday, February 8th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $38.20.
Phibro Animal Health (NASDAQ PAHC) traded down $0.05 during mid-day trading on Wednesday, reaching $40.20. The company’s stock had a trading volume of 131,962 shares, compared to its average volume of 98,449. The company has a quick ratio of 1.75, a current ratio of 3.12 and a debt-to-equity ratio of 1.82. The stock has a market cap of $1,625.73, a price-to-earnings ratio of 26.27, a PEG ratio of 2.87 and a beta of 0.97. Phibro Animal Health has a 1-year low of $26.70 and a 1-year high of $41.05.
Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Monday, February 5th. The company reported $0.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.06. The business had revenue of $205.90 million during the quarter, compared to analyst estimates of $194.90 million. Phibro Animal Health had a return on equity of 32.61% and a net margin of 6.67%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.39 EPS. sell-side analysts expect that Phibro Animal Health will post 1.69 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, March 7th will be issued a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date is Tuesday, March 6th. Phibro Animal Health’s payout ratio is presently 26.14%.
In other Phibro Animal Health news, VP Daniel M. Bendheim sold 3,960 shares of Phibro Animal Health stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $40.06, for a total transaction of $158,637.60. Following the completion of the transaction, the vice president now owns 3,860 shares of the company’s stock, valued at approximately $154,631.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel M. Bendheim sold 13,162 shares of the business’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $40.00, for a total value of $526,480.00. Following the transaction, the vice president now directly owns 3,425 shares of the company’s stock, valued at approximately $137,000. The disclosure for this sale can be found here. Insiders have sold a total of 240,056 shares of company stock valued at $9,052,620 in the last ninety days. Insiders own 51.88% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Equities Focus and is the sole property of of Equities Focus. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.equitiesfocus.com/2018/03/14/phibro-animal-health-pahc-receiving-somewhat-positive-news-coverage-analysis-finds.html.
About Phibro Animal Health
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.